Staff Profile

Although I no longer work at the University I have maintained my enthusiasm for improving outcomes in cancer. I have cofounded a company (Rarecan Limited) which helps to link people affected by rare forms of cancer with research groups which have new approaches to prevention, diagnosis or treatment.

For more details please visit https://rarecan.com

Research Interests

I am no longer directly involved in research

I give an annual seminar to postdocs on the application process fot NHS Research Ethics approval

• Ciardullo C, Szoltysek K, Zhou P, Pietrowska M, Marczak L, Willmore E, Enshaei A, Walaszczyk A, Ho JY, Rand V, Marshall S, Hall AG, Harrison CJ, Soundararajan M, Eswaran J. Low BACH2 expression predicts adverse outcome in chronic lymphocytic leukaemia. Cancers 2022, 14(1), 23.
• Szoltysek K, Ciardullo C, Zhou P, Walaszczyk A, Willmore E, Rand V, Marshall S, Hall A, Harrison CJ, Eswaran J, Soundararajan M. Dap kinase-related apoptosis-inducing protein kinase 2 (Drak2) is a key regulator and molecular marker in chronic lymphocytic leukemia. International Journal of Molecular Sciences 2020, 21(20), 7663.
• Zhou P, Blain AE, Newman AM, Zaka M, Chagaluka G, Adlar F, Offor UT, Broadbent C, Chaytor L, Whitehead A, Hall A, O'Connor H, Van Noorden S, Lampert I, Bailey S, Molyneux E, Bacon CM, Bomken S, Rand V. Sporadic and endemic Burkitt lymphoma have frequent FOXO1 mutations but distinct hotspots in the AKT recognition motif. Blood Advances 2019, 3(14), 2118-2127.
• Rees G, Salto-Tellez M, Lee JL, Oien K, Verrill C, Freeman A, Mirabile I, West NP, Cheang M, Rodriguez-Justo M, Howlett E, Moretti L, Da Silva M, Nacs W, Hartridge-Lambert S, Beecham JM, Traub S, Katugampola S, Blagden S, Morden J, Robinson M, James J, Jones LJ, Craig C, Sloan P, Thomas GJ, Elliott P, Driskell OJ, Hall A. Training and accreditation standards for pathologists undertaking clinical trial work. Journal of Pathology: Clinical Research 2019, Epub ahead of print.
• Macklin PS, Hall A, Lee J, Hair J, Speirs V, Thomas GJ, Oien KA, Verrill C. Barriers to the release of human tissue for clinical trials research in the UK: A national survey of cellular pathology laboratories on behalf of the National Cancer Research Institute's Cellular Molecular Pathology (CM-Path) initiative. Journal of Clinical Pathology 2018, 72(1), 52-57.
• Zhou P, Newman AM, Adlar F, Broadbent C, Blain A, Hall A, Whitehead A, Chagaluka G, Molyneux E, Bailey S, Bacon CM, Bomken S, Rand V. Investigation of FOXO1 mutations in paediatric endemic and sporadic Burkitt lymphoma. In: Sixth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma. 2018, Rotterdam, Netherlands: British Journal of Haematology.
• Ciardullo C, Willmore E, Enshaei A, Zhou P, Rand V, Soundararajan M, Hall A, Harrison C, Eswaran J. BACH2 and BCL6 Cooperatively Fuction as Tumour Suppressors in CLL. In: 21st Congress of the European Hematology Association. 2016, Copenhagen, Denmark: Ferrata Storti Foundation.
• Ciardullo C, Zhou P, Willmore E, Harrison CJ, Hall A, Eswaran J, Soundararajan M. Impact of the apoptotic regulator DRAK2 in chronic lymphocytic leukemia. In: XXXVI World Congress of the International Society of Hematology. 2016, Glasgow: Wiley-Blackwell.
• Ciardullo C, Willmore E, Zhou P, Rand V, Harrison C, Hall A, Eswaran J, Soundararajan M. Impact of the apoptotic regulator DRAK2 in chronic lymphocytic leukemia. In: 21st Congress of the European Hematology Association. 2016, Copenhagen, Denmark: Fondazione Ferrata Storti.
• Mistry G, Page A, Ellershaw C, Malik G, Gamble A, Hall A, Jacques TS, Tweddle DA. The National Children's Cancer and Leukaemia Group Tissue Bank similar to Facilitating a Comprehensive Range of Paediatric Oncology Research. In: 48th Congress of the International Society of Paediatric Oncology (SIOP). 2016, Dublin, Ireland: John Wiley & Sons, Inc.
• Dormon K, Latif ES, Bashton M, Pal D, Selby M, Blair H, Rand V, Hall AG, Vormoor J, Heidenreich O. A Whole Genome In Vivo Crispr Screen in Primary ALL Predicts Leukaemic Relapse. In: ASH 2015 Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
• Sava GP, Speedy HE, Di Bernardo MC, Dyer MJS, Holroyd A, Sunter NJ, Marr H, Mansouri L, Deaglio S, Karabon L, Frydecka I, Jamroziak K, Woszczyk D, Juliusson G, Smedby KE, Jayne S, Majid A, Wang Y, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS. Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. Leukemia 2015, 29(3), 748-751.
• Davies C, Hogarth LA, Mackenzie KL, Hall AG, Lock RB. p21^WAF1 modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia. Cell Cycle 2015, 14(22), 3602-3612.
• Nicholson L, Evans C, Matheson E, Minto L, Keilty C, Sanichar M, Case M, Schwab C, Williamson D, Rainer J, Harrison C, Kofler R, Hall AG, Rednern CPF, Wheaton AD, Irving JAE. Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition. British Journal of Haematology 2015, 171(4), 595–605.
• Eswaran J, Sinclair P, Heidenreich O, Irving J, Russell LJ, Hall A, Calado DP, Harrison CJ, Vormoor J. The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia 2015, 29(8), 1623-1631.
• Speedy HE, Di Bernardo MC, Sava GP, Dyer MJS, Holroyd A, Wang YF, Sunter NJ, Mansouri L, Juliusson G, Smedby KE, Roos G, Jayne S, Majid A, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nature Genetics 2014, 46(1), 56-60.
• Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Nowak D, Thoennissen GB, Rand V, Graeber TG, Koeffler HP, Carroll WL, Willman CL, Hall AG, Igarashi K, Melnick A, Müschen M. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nature Medicine 2013, 19(8), 1014-1022.
• Rehe K, Wilson K, Bomken S, Williamson D, Irving J, den Boer ML, Stanulla M, Schrappe M, Hall AG, Heidenreich O, Vormoor J. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Molecular Medicine 2013, 5(1), 38-51.
• Nicholson L, Knight T, Matheson E, Minto L, Case M, Sanichar M, Bomken S, Vormoor J, Hall A, Irving J. Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 2012, 51(3), 250-256.
• de Brito LR, Batey MA, Zhao Y, Squires MS, Maitland H, Leung HY, Hall AG, Jackson G, Newell DR, Irving JAE. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma. Leukemia Research 2011, 35(9), 1233-1240.
• Coulthard SA, Redfern CPF, Vikingsson S, Lindqvist-Appell M, Skoglund K, Jakobsen-Falk I, Hall AG, Taylor GA, Hogarth LA. Increased Sensitivity to Thiopurines in Methylthioadenosine Phosphorylase-Deleted Cancers. Molecular Cancer Therapeutics 2011, 10(3), 495-504.
• Davies C, Hogarth LA, Dietrich PA, Bachmann PS, Mackenzie KL, Hall AG, Lock RB. p53-independent Epigenetic Repression of the p21^WAF1 Gene in T-cell Acute Lymphoblastic Leukemia. Journal of Biological Chemistry 2011, 286(43), 37639-37650.
• Al-Balool HH, Weber D, Liu Y, Wade M, Guleria K, Nam PL, Clayton J, Rowe W, Coxhead J, Irving J, Elliott DJ, Hall AG, Santibanez-Koref M, Jackson MS. Post-transcriptional exon shuffling events in humans can be evolutionarily conserved and abundant. Genome Research 2011, 21(11), 1788-1799.
• Nicholson L, Evans C, Matheson EC, Minto L, Keilty C, Schwab C, Harrison CJ, Hall AG, Redfern C, Whetton A, Irving J. Quantitative Proteomic Analysis Reveals Maturation As a Mechanism Underlying Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia and PAX5 As a Re-Sensitising Therapeutic Target. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Pratt G, Fenton JAL, Allsup D, Fegan C, Morgan GJ, Jackson G, Sunter NJ, Hall AG, Irving JAE, Allan JM. A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma. British Journal of Haematology 2010, 150(3), 371-373.
• Peasland A, Matheson E, Hall A, Irving J. Alternative splicing of hMLH1 in childhood acute lymphoblastic leukaemia and characterisation of the variably expressed Δ9/10 isoform as a dominant negative species. Leukemia Research 2010, 34(3), 322-327.
• Crowther-Swanepoel D, Broderick P, Di Bernardo MC, Dobbins SE, Torres M, Mansouri M, Ruiz-Ponte C, Enjuanes A, Rosenquist R, Carracedo A, Jurlander J, Campo E, Juliusson G, Montserrat E, Smedby KE, Dyer MJS, Matutes E, Dearden C, Sunter NJ, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Parker A, Oscier D, Allan JM, Catovsky D, Houlston RS. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nature Genetics 2010, 42(2), 132-136.
• Best A, Matheson E, Minto L, Hall AG, Irving JAE. Mismatch repair and the downstream target genes, PAX5 and Ikaros, in childhood acute lymphoblastic leukemia. Leukemia Research 2010, 34(8), 1098-1102.
• Nicholson L, Hall AG, Redfern CP, Irving J. NF kappa B modulators in a model of glucocorticoid resistant, childhood acute lymphoblastic leukemia. Leukemia Research 2010, 34(10), 1366-1373.
• Allan JM, Sunter NJ, Bailey JR, Pettitt AR, Harris RJ, Pepper C, Fegan C, Hall AG, Deignan L, Bacon CM, Pointon JC, Houlston RS, Broderick P, Mainou-Fowler T, Jackson GH, Summerfield G, Evans PA, Strefford JC, Parker A, Oscier D, Pratt G, Allsup DJ. Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. Leukemia 2010, 24(4), 877-881.
• Sulong S, Moorman AV, Irving JAE, Strefford JC, Konn ZJ, Case MC, Minto L, Barber KE, Parker H, Wright SL, Stewart ARM, Bailey S, Bown NP, Hall AG, Harrison CJ. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood 2009, 113(1), 100-107.
• Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, Kreil S, Jones A, Score J, Metzgeroth G, Oscier D, Hall AG, Brandts C, Serve H, Reiter A, Chase AJ, Cross NCP. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009, 113(24), 6182-6192.
• Johnson N, Speirs V, Curtin NJ, Hall AG. A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer. Breast Cancer Research and Treatment 2008, 111(1), 55-63.
• Di Bernardo M, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, Sullivan K, Vijayakrishnan J, Wang Y, Pittman A, Sunter N, Hall AG, Dyer M, Matutes E, Dearden C, Mainou-Fowler T, Jackson GH, Summerfield G, Harris R, Pettitt A, Hillmen P, Allsup D, Bailey J, Pratt G, Pepper C, Fegan C, Allan JM, Catovsky D, Houlston R. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nature Genetics 2008, 40(10), 1204-1210.
• Bungaro, S., Irving, J.A.E., Tussiwand, R., Mura, R., Minto, C.L.J., Molteni, C., Citterio, M., Hall, A.G., Biondi, A., Cazzaniga, G. Genomic analysis of different clonal evolution in a twin pair with t(12;21) positive acute lymphoblastic leukemia sharing the same prenatal clone [8]. Leukemia 2008, 22(1), 208-211.
• Case MC, Matheson E, Minto L, Hassan R, Harrison CJ, Bown NP, Bailey S, Vormoor J, Hall AG, Irving JAE. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Research 2008, 68(16), 6803-6809.
• Parker H, An Q, Barber K, Case MC, Davies TL, Konn Z, Stewart A, Wright S, Griffiths M, Ross FM, Moorman AV, Hall AG, Irving JAE, Harrison CJ, Strefford JC. The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1. Genes, Chromosomes and Cancer 2008, 47(12), 1118-1125.
• Hogarth LA, Redfern CPF, Teodoridis J, Hall AG, Anderson HL, Case MC, Coulthard SA. The effect of thiopurine drugs on DNA methylation in relation to TPMT expression. Biochemical Pharmacology 2008, 76(8), 1024-1035.
• An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Moorman AV, Parker H, Griffiths M, Ross FM, Davies T, Hall AG, Harrison CJ, Irving JA, Strefford JC. Variable breakpoints target PAX5 in patients with dicentric chromosomes: A model for the basis of unbalanced translocations in cancer. Proceedings of the National Academy of Sciences 2008, 105(44), 17050-17054.
• Matheson EC, Hogarth LA, Case MC, Irving JAE, Hall AG. DHFR and MSH3 co-amplification in childhood acute lymphoblastic leukaemia, in vitro and in vivo. Carcinogenesis 2007, 28(6), 1341-1346.
• Carr, J., Bown, N.P., Case, M.C., Hall, A.G., Lunec, J., Tweddle, D.A. High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays. Cancer Genetics and Cytogenetics 2007, 172(2), 127-138.
• Łastowska MA, Viprey V, Santibanez-Koref MF, Wappler I, Peters HH, Cullinane C, Roberts P, Hall AG, Tweddle DA, Pearson ADJ, Lewis I, Burchill S, Jackson MS. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 2007, 26(53), 7432-7444.
• Hall, A.G., Sulong, S., Harrison, C., Minto, C.L.J., Bown, N.P., Case, M.C., Bailey, S., Irving, J.A.E. Assessment of aneuploidy in childhood acute lymphoblastic leukaemia using high density oligonucleotide arrays. Blood 2006, 108(11).
• Syed, A.A., Irving, J.A.E., Redfern, C.P.F., Hall, A.G., Unwin, N.C., White, M.J.R., Bhopal, R.S., Weaver, J.U. Association of glucocorticoid receptor polymorphism A3669G in exon 9β with reduced central adiposity in women. Obesity 2006, 14(5), 759-764.
• Sulong, S., Irving, J.A.E., Case, M.C., Minto, C.L.J., Bown, N., Bailey, S., Harrison, C., Hall, A.G. Comprehensive analysis of p16(INK4a) in childhood acute lymphoblastic leukemia reveals homozygous deletion, haploinsufficiency and acquired isodisomy at the 9p locus with intact p16(INK4a). Blood 2006, 108(11).
• Anderson RJ, Cairns D, Cardwell WA, Case MC, Groundwater PW, Hall AG, Hogarth LA, Jones AL, Meth-Cohn O, Suryadevara P, Tindall A, Thoene JG. Design, synthesis and initial in vitro evaluation of novel prodrugs for the treatment of cystinosis. Letters in Drug Design & Discovery 2006, 3(5), 336-345.
• Leslie M, Case MC, Hall AG, Coulthard SA. Expression levels of asparagine synthetase in blasts from children and adults with acute lymphoblastic leukaemia. British Journal of Haematology 2006, 132(6), 740-742.
• Schmidt S, Irving JAE, Minto CLJ, Matheson E, Nicholson L, Ploner A, Parson W, Kofler A, Amort M, Erdel M, Hall AG, Kofler R. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor. The FASEB Journal 2006, 20(14), E2087-E2097.
• Irving, J.A.E., Minto, C.L.J., Matheson, E., Case, M.C., Bailey, S., Bown, N.P., Hassan, R., Harrison, C., Hall, A.G. Mutation in genes impacting on the RAS-RAF-MEK-ERK pathway are found at high incidence in childhood acute lymphoblastic leukemia at both diagnosis and at relapse. Blood 2006, 108(11), 160B-161B.
• Pemberton LC, Levett DL, Skinner R, Hall AG, Hanley JP. Novel mutations in a child with congenital amegakaryocytic thrombocytopenia. British Journal of Haematology 2006, 135(5), 742-743.
• Meier, M., den Boer, M., Hall, A.G., Irving, J.A.E., Passier, M., Minto, C.L.J., van Wering, E., Janka-Schaub, G., Pieters, R. Reply to 'ATM variants and predisposition to childhood T-lineage acute lymphoblastic leukaemia' by Gumy-Pause et al. [6]. Leukemia 2006, 20(3), 527.
• Velangi M, Matheson E, Hall AG, Irving JAE. Detecting mismatch repair defects in myeloma. In: Brown RD; Ho PJ, ed. Multiple Myeloma. Totowa, N.J: Humana Press, Inc, 2005, pp.269-77.
• Irving, J.A.E., Minto, C.L.J., Bailey, S., Hall, A.G. Loss of heterozygosity and somatic mutations of the Glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course. Cancer Research 2005, 65(21), 9712-9718.
• Irving JAE, Bloodworth LC, Bown NP, Case MC, Hogarth LA, Hall AG. Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis. Cancer Research 2005, 65(8), 3053-3058.
• Meier, M., den Boer, M., Hall, A.G., Irving, J.A.E., Passier, M., Minto, C.L.J., van Wering, E., Janka-Schaub, G., Pieters, R. Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia. Leukemia 2005, 19(11), 1887-1895.
• Sulong, S., Case, M.C., Minto, C.L.J., Wilkins, B., Hall, A.G., Irving, J. The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia. British Journal of Haematology 2005, 130(6), 964-965.
• Pal, S., Bandyopadhyay, S., Chatterjee, M., Bhattacharya, D., Minto, C.L.J., Hall, A.G., Mandal, C. Antibodies against 9-O-acetylated sialoglycans: A potent marker to monitor clinical status in childhood acute lymphoblastic leukemia. Clinical Biochemistry 2004, 37(5), 395-403.
• Velangi MR, Matheson EC, Taylor PRA, Jackson GH, Hall AG, Irving JAE. BRAF gene is not mutated in mismatch repair-proficient or -deficient plasma cell dyscrasias . Leukemia 2004, 18(3), 658-659.
• Velangi MR, Matheson EC, Morgan GJ, Jackson GH, Taylor PRA, Hall AG, Irving JAE. DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma. Carcinogenesis 2004, 25(10), 1795-1803.
• Lovat, P.E., Di Sano, F., Corazzari, M., Fazi, B., Donnorso, R., Pearson, A.D.J., Hall, A.G., Redfern, C.P.F., Piacentini, M. Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. Journal of the National Cancer Institute 2004, 96(17), 1288-1299.
• Meier, M., Den Boer, M.L., Hall, A.G., Irving, J.A.E., Passier, M., Minto, C.L.J., Van Wering, E.R., Janka-Schaub. G.E., Pieters. R. Genetic variants of ataxia telangiectasia mutated (ATM) and susceptibility for childhood T-lineage acute lymphoblastic leukemia. Blood 2004, 104(11), 524A-524A.
• Syed, A.A., Irving, J.A.E., Redfern, C.P.F., Hall, A.G., Unwin, N.C., White, M., Bhopal, R., Alberti, K., Weaver, J.U. Low Prevalence of the N363S Polymorphism of the Glucocorticoid Receptor in South Asians Living in the United Kingdom. Journal of Clinical Endocrinology and Metabolism 2004, 89(1), 232-235.
• Coulthard SA, Matheson EC, Hall AG, Hogarth LA. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment. In: Joint 11th International and 9th European Symposium on Purines and Pyrimidines. 2004, Man Egmond Aan Zee, Netherlands: Nucleosides, Nucleotides and Nucleic Acids: Taylor & Francis Inc.
• Irving JAE, O'Brien S, Lennard A, Minto CLJ, Lin F, Hall AG. Use of Denaturing HPLC for Detection of Mutations in the BCR-ABL Kinase Domain in Patients Resistant to Imatinib. Clinical Chemistry 2004, 50(7), 1233-1237.
• Matheson EC, Hall AG. Assessment of mismatch repair function in leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia. Carcinogenesis 2003, 24(1), 31-38.
• Kearns P, Chrzanowska-Lightowlers ZMA, Pieters R, Veerman A, Hall AG. Expression of GSTM isoforms in childhood acute lymphoblastoid leukaemia. British Journal of Haematology 2003, 120(1), 80-88.
• MacPartlin M, Homer E, Robinson H, McCormick CJ, Crouch DH, Durant ST, Matheson EC, Hall AG, Gillespie DAF, Brown R. Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX. Oncogene 2003, 22(6), 819-825.
• Mason PA, Matheson EC, Hall AG, Lightowlers RN. Mismatch repair activity in mammalian mitochondria. Nucleic Acids Research 2003, 31(3), 1052-1058.
• Hall AG, Coulthard SA, Irving JAE. Molecular diagnostics: a healthcare perspective. Expert Review of Molecular Diagnostics 2003, 3(1), 13-16.
• Kearns PR, Chrzanowska-Lightowlers ZMA, Pieters R, Veerman A, Hall AG. Mu class glutathione S-transferase mRNA isoform expression in acute lymphoblastic leukaemia. British Journal of Haematology 2003, 120(1), 80-88.
• Lewandowicz GM, Britt P, Elgie AW, Williamson CJ, Coley HM, Hall AG, Sargent JM. Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer. Gynecologic Oncology 2002, 85(2), 298-304.
• Nouman, G., Anderson, J.J., Wood, K., Lunec, J., Hall, A.G., Reid, M.M., Angus, B. Loss of nuclear expression of the p33ING1b inhibitor of growth protein in childhood acute lymphoblastic leukaemia. Journal of Clinical Pathology 2002, 55(8), 596-601.
• Hall AG, Irving JAE. New drugs, new drug resistance mechanisms. Expert Review of Anticancer Therapy 2002, 2(3), 239-240.
• Coulthard, S.A., Hogarth, L.A., Little, M.A., Matheson, E., Redfern, C.P.F., Minto, C.L.J., Hall, A.G. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Molecular Pharmacology 2002, 62(1), 102-109.
• McInerney TL, Matheson E, Hall A. Drug discovery - High throughput automated 2-D gel analysis - Tutorial: Proteomic analysis with nonlinear dynamics' progenesis image analysis software. Genetic Engineering News 2001, 21(17), 32.
• Hogarth, L.A., Little, M.A., Minto, C.L.J., Redfern, C.P.F., Hall, A.G., Coulthard, S. High thiopurine methyltransferase expression confers different levels of resistance with 6-thioguanine compared to 6-mercaptopurine. Leukemia 2001, 15(3), 484-484.
• Hogarth, L.A., Little, M.A., Minto, C.L.J., Redfern, C.P.F., Hall, A.G., Coulthard, S.A. In vitro evidence for differences in 6-mercaptopurine versus 6-thioguanine metabolism depending on TPMT status. British Journal of Cancer 2001, 85(Supplement 1), 60-60.
• Irving JAE, Hall AG. Mismatch repair defects as a cause of resistance to cytotoxic drugs. Expert Review of Anticancer Therapy 2001, 1(1), 149-158.
• Nouman, G.S., Anderson, J.J., Lunec, J., Hall, A.G., Reid, M.M., Angus, B. p33(ING1b) tumour suppresser protein expression in childhood acute lymphoblastic leukaemia by immunohistochemistry. Journal of Pathology 2001, 195, 34A-34A.
• Daly AK, Hall AG. Pharmacogenetics of cytotoxic drugs. Expert Review of Anticancer Therapy 2001, 1(2), 301-308.
• Kearns PR, Pieters R, Rottier MMA, Pearson ADJ, Hall AG. Raised blast glutathione levels are associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 2001, 97(2), 393-398.
• Coulthard SA, Hall AG. Recent advances in the pharmacogenomics of thiopurine methyltransferase. The Pharmacogenomics Journal 2001, 1(4), 254-261.
• Velangi MR, Irving JAE, Taylor PRA, Morgan G, Jackson GH, Hall AG. The presence of mismatch repair defects in plasma cell dyscrasias. Blood 2001, 98(11 part 2), 306B no. 4967.
• Bailey, S., Hall, A. G., Pearson, A. D. J., Redfern, C. P. F. The role of AP-1 in glucocorticoid resistance in leukaemia. Leukemia 2001, 15(3), 391-397.
• Hall, A.G., Hamilton, P., Minto, C.L.J., Coulthard, S.A. The use of denaturing high-pressure liquid chromatography for the detection of mutations in thiopurine methyltransferase. Journal of Biochemical and Biophysical Methods 2001, 47(1-2), 65-71.
• Lodge, A.J., Hall, A.G., Reid, M.M., McIntosh, G., Steward, M., Anderson, J.J., Horne, C.H.W., Angus, B. Topoisomerase IIα and IIβ expression in childhood acute lymphoblastic leukaemia: Relation to prognostic factors and clinical outcome. Journal of Clinical Pathology 2001, 54(1), 31-36.
• Coulthard, S., Rabello, C., Robson, J., Howell, C., Minto, L., Middleton, P., Gandhi, M., Jackson, G., McLelland, J., O'Brien, H., Smith, S., Reid, M., Pearson, A., Hall, A. A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. British Journal of Haematology 2000, 110(3), 599-604.
• Estlin EJ, Lowis SP, Hall AG. Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia. British Journal of Haematology 2000, 110(1), 29-40.
• McLeod HL, Coulthard S, Thomas AE, Pritchard SC, King DJ, Richards SM, Eden OB, Hall AG, Gibson BES. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. British Journal of Haematology 1999, 105(3), 696-700.
• Den Boer ML, Pieters R, Kazemier KM, Janka-Schaub GE, Henze G, Creutzig U, Kaspers GJL, Kearns PR, Hall AG, Pearson ADJ, Veerman AJP. Different expression of glutathione S-transferase α, µ and π in childhood acute lymphoblastic and myeloid leukaemia. British Journal of Haematology 1999, 104(2), 321-327.
• Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 1999, 93(8), 2671-2678.
• McIntosh, G., Lodge, A., Watson, P., Hall, A.G., Wood, K., Anderson, J.J., Angus, B., Horne, C., Milton, I. NCL-CD10-270: A new monoclonal antibody recognizing CD10 in paraffin- embedded tissue. American Journal of Pathology 1999, 154(1), 77-82.
• Hall AG. The role of glutathione in the regulation of apoptosis. European Journal of Clinical Investigation 1999, 29(3), 238-245.
• Lodge AJ, Hall AG, Anderson JJ, McIntosh GG, Steward M, Reid MM, Horne CHW, Angus B.

  A study of the prognostic significance of topoisomerase IIα in childhood acute lymphoblastic Leukaemia. In: 177th Meeting of The Pathological Society of Great Britain and Ireland. 1998, University of Leicester, Leicestershire, UK: Journal of Pathology: John Wiley & Sons Ltd.

• MacLean FR, Skinner R, Hall AG, English M, Pearson ADJ. Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation. Cancer Chemotherapy and Pharmacology 1998, 41(5), 413-416.
• Kearns PR, Hall AG. Glutathione and the response of malignant cells to chemotherapy. Drug Discovery Today 1998, 3(3), 113-121.
• Kearns PR, Pieters R, Rottier MMA, Veerman AJP, Schmiegolow K, Pearson ADJ, Hall AG. Glutathione levels in leukaemic blasts. British Journal of Cancer 1998, 78(Suppl. 1), 25-25.
• Coulthard SA, Howell CI, Robson J, Hall AG. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood 1998, 92(8), 2856-2862.
• Estlin EJ, Hall AG, Lunec J, Newell DR, Pearson ADJ, Taylor GA. Thymidylate synthase expression in nolatrexed and methotrexate-resistant human leukaemia cell lines. British Journal of Cancer 1998, 78(Suppl. 1), 25-25.
• Yule SM, Kearns PR, Hall AG. Alkylating agent resistance in pediatric oncology. International Journal of Pediatric Hematology - Oncology 1997, 4(6), 613-628.
• Maung ZT, Reid MM, Proctor SJ, Taylor PRA, Matheson E, Hall AG. Corticosteroid resistance: An important biological difference between childhood and adult acute lymphoblastic leukemia. In: DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA II. 1997, POSTSTRASSE 22, 7000 CHUR, SWITZERLAND: HARWOOD ACADEMIC PUBL GMBH.
• Jackson AP, Hall AG, McLelland J. Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine. British Journal of Dermatology 1997, 136(1), 133-134.
• Hall AG, Rabello C, Jackson GH, Gandhi MK, O'Brien H. Congenital deficiency of thiopurine methyltransferase as a cause of pancytopenia in patients treated with azathioprine. British Journal of Haematology 1996, 93(supplement 2), 789.
• Masters JRW, Thomas R, Hall AG, Hogarth LA, Matheson EC, Cattan AR, Lohrer H. Sensitivity of testis tumour cells to chemotherapeutic drugs: Role of detoxifying pathways. European Journal of Cancer 1996, 32(7), 1248-1253.
• Hogarth LA, English M, Price L, Wyllie R, Pearson ADJ, Hall AG. The effect of treatment with high dose melphalan, cisplatin or carboplatin on levels of glutathione in plasma, erythrocytes, mononuclear cells and urine. Cancer Chemotherapy and Pharmacology 1996, 37(5), 479-485.
• Ghazal-Aswad, S., Hall, A. G., George, M., Sinha, D., Lind, M., Calvert, A. H., Sunter, J. P., Newell, D. R. The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients. British Journal of Cancer 1996, 74(3), 468-473.